These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 19931877)

  • 41. [Variability in the recommendations for the clinical management of osteoporosis].
    Sanfélix-Genovés J; Catalá-López F; Sanfélix-Gimeno G; Hurtado I; Baixauli C; Peiró S
    Med Clin (Barc); 2014 Jan; 142(1):15-22. PubMed ID: 23332628
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bone quality: educational tools for patients, physicians, and educators.
    Shams J; Spitzer AB; Kennelly AM; Tosi LL
    Clin Orthop Relat Res; 2011 Aug; 469(8):2248-59. PubMed ID: 21400004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characteristics associated with anti-osteoporosis medication use: data from the Global Longitudinal Study of Osteoporosis in Women (GLOW) USA cohort.
    Guggina P; Flahive J; Hooven FH; Watts NB; Siris ES; Silverman S; Roux C; Pfeilschifter J; Greenspan SL; Díez-Pérez A; Cooper C; Compston JE; Chapurlat R; Boonen S; Adachi JD; Anderson FA; Gehlbach S;
    Bone; 2012 Dec; 51(6):975-80. PubMed ID: 22964142
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quality and performance measures in bone densitometry. Part 2: fracture risk.
    Glüer CC; Lu Y; Engelke K
    Osteoporos Int; 2006 Oct; 17(10):1449-58. PubMed ID: 16821004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association Between FGF-23 Levels and Risk of Fracture in Women With Systemic Sclerosis.
    Cantero-Nieto L; Álvarez-Cienfuegos A; García-Gómez JA; Ríos-Fernández R; Robledo G; Ortego-Centeno N
    J Clin Densitom; 2021; 24(3):362-368. PubMed ID: 32600830
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Osteoporosis Drug Treatment Update.
    Oliveira LG; Carneiro MLRG; Souza MPG; Souza CG; Moraes FB; Camargo FL
    Rev Bras Ortop (Sao Paulo); 2021 Oct; 56(5):550-557. PubMed ID: 34733425
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Letter to the editor: regarding "The utility and limitations of FRAX: a US perspective".
    Czerwinski E
    Curr Osteoporos Rep; 2012 Mar; 10(1):1-2; author reply 3. PubMed ID: 22249581
    [No Abstract]   [Full Text] [Related]  

  • 48. Erratum to "The activity of a Spanish bone densitometry unit revisited under the point of view of FRAX" <[Reumatol Clin 8 (2012) 179-183]>.
    Gómez-Vaquero C; Bianchi M; Santo P; Roig-Vilaseca D; Narváez J; Nolla JM
    Reumatol Clin; 2017; 13(4):248. PubMed ID: 28668196
    [No Abstract]   [Full Text] [Related]  

  • 49. Cases of Compound Fracture Treated Antiseptically.
    Dewar
    Glasgow Med J; 1872 Nov; 5(1):125-127. PubMed ID: 30432805
    [No Abstract]   [Full Text] [Related]  

  • 50. Adherence to the Mediterranean Diet and Bone Fracture Risk in Middle-Aged Women: A Case Control Study.
    Palomeras-Vilches A; Viñals-Mayolas E; Bou-Mias C; Jordà-Castro M; Agüero-Martínez M; Busquets-Barceló M; Pujol-Busquets G; Carrion C; Bosque-Prous M; Serra-Majem L; Bach-Faig A
    Nutrients; 2019 Oct; 11(10):. PubMed ID: 31635237
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort.
    Sanfélix-Genovés J; Sanfélix-Gimeno G; Peiró S; Hurtado I; Fluixà C; Fuertes A; Campos JC; Giner V; Baixauli C
    Osteoporos Int; 2013 Mar; 24(3):1045-55. PubMed ID: 22618269
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Assessment of subjetive risk factors for osteoporosis in front of objetive registration by FRAX tool. VALSUFRAX study preview].
    Blasco Valle M; Sanjuán Domingo R; Ferreras Amez JM; Aldea Molina E
    Aten Primaria; 2011 Sep; 43(9):507-9. PubMed ID: 21377238
    [No Abstract]   [Full Text] [Related]  

  • 53. Prediction of absolute risk of fragility fracture at 10 years in a Spanish population: validation of the WHO FRAX ™ tool in Spain.
    Azagra R; Roca G; Encabo G; Prieto D; Aguyé A; Zwart M; Güell S; Puchol N; Gene E; Casado E; Sancho P; Solà S; Torán P; Iglesias M; Sabaté V; López-Expósito F; Ortiz S; Fernandez Y; Diez-Perez A
    BMC Musculoskelet Disord; 2011 Jan; 12():30. PubMed ID: 21272372
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Fracture Risk Assessment Tool (FRAX®): applications in clinical practice.
    Watts NB
    J Womens Health (Larchmt); 2011 Apr; 20(4):525-31. PubMed ID: 21438699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary care use of FRAX: absolute fracture risk assessment in postmenopausal women and older men.
    Siris ES; Baim S; Nattiv A
    Postgrad Med; 2010 Jan; 122(1):82-90. PubMed ID: 20107292
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [FRAX® thresholds to identify people with high or low risk of osteoporotic fracture in Spanish female population].
    Azagra R; Roca G; Martín-Sánchez JC; Casado E; Encabo G; Zwart M; Aguyé A; Díez-Pérez A;
    Med Clin (Barc); 2015 Jan; 144(1):1-8. PubMed ID: 24461732
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Usefulness of FRAX tool for the management of osteoporosis in the Spanish female population].
    Azagra Ledesma R; Prieto-Alhambra D; Encabo Duró G; Casado Burgos E; Aguyé Batista A; Díez-Pérez A;
    Med Clin (Barc); 2011 May; 136(14):613-9. PubMed ID: 21349558
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Fracture risk calculated with the FRAX index in patients with osteoporosis treated and untreated].
    Roig Vilaseca D; Gómez Vaquero C; Hoces Otero C; Nolla JM
    Med Clin (Barc); 2010 Feb; 134(5):189-93. PubMed ID: 19931877
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.